Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their price targets and ratings for several companies. Fusion Pharmaceuticals' target was raised by Raymond James, who also upgraded the stock to Strong Buy. Organogenesis and Aspen Aerogels had their targets raised by BTIG and Canaccord Genuity, respectively, both maintaining Buy ratings. Pinterest's target was increased by Wedbush, but the rating remained Neutral. Expedia's target was raised by BTIG with a Buy rating. Bristol-Myers Squibb's target was cut by B of A Securities, yet the rating stayed at Buy. Meta Platforms' target was significantly raised by Wedbush, maintaining an Outperform rating. Milestone Pharmaceuticals had its target cut by TD Cowen, but kept an Outperform rating. Global Partners' target was raised by Stifel with a Buy rating. MercadoLibre also saw a target increase by Wedbush, maintaining an Outperform rating.
December 27, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity raised Aspen Aerogels' price target from $13 to $17, maintaining a Buy rating.
The increase in price target and the continuation of a Buy rating suggest that Aspen Aerogels is still seen as a strong investment, potentially leading to a rise in its stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
BTIG raised Expedia Group's price target from $150 to $175 and maintained a Buy rating.
The increased price target and maintained Buy rating indicate a positive outlook for Expedia Group, which could lead to increased investor interest and a potential stock price increase.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Raymond James raised Fusion Pharmaceuticals' price target from $12 to $15 and upgraded the stock to Strong Buy.
The upgrade to Strong Buy and raised target price suggest a positive outlook for Fusion Pharmaceuticals, which could lead to an increase in investor confidence and a potential rise in stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Stifel raised Global Partners' price target from $40 to $44 and maintained a Buy rating.
The raised price target and Buy rating indicate a positive view on Global Partners, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Wedbush raised MercadoLibre's price target from $1,700 to $1,800 and maintained an Outperform rating.
The increase in price target and the Outperform rating suggest that MercadoLibre is expected to continue its growth trajectory, which could positively influence its stock price.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Wedbush significantly raised Meta Platforms' price target from $350 to $420 and maintained an Outperform rating.
The substantial increase in Meta Platforms' price target and the Outperform rating suggest strong confidence from Wedbush, which could lead to significant investor interest and a potential stock price rally.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
BTIG increased Organogenesis Holdings' price target from $4 to $6 and maintained a Buy rating.
The raised price target and maintained Buy rating indicate a favorable analyst outlook, which may contribute to positive investor sentiment and a potential uptick in the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
B of A Securities cut Bristol-Myers Squibb's price target from $72 to $68 but maintained a Buy rating.
The reduction in price target is negative, but the maintained Buy rating could offset the impact, leading to a neutral short-term effect on the stock price.
CONFIDENCE 70
IMPORTANCE 65
RELEVANCE 70
NEUTRAL IMPACT
Wedbush raised Pinterest's price target from $32 to $35 but maintained a Neutral rating.
The raised price target is positive, but the Neutral rating suggests that Wedbush does not see significant upside potential at this time, which could result in a neutral impact on the stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
TD Cowen lowered Milestone Pharmaceuticals' price target from $17 to $9 but maintained an Outperform rating.
The significant cut in price target is a negative signal, and despite the Outperform rating, the stock may face downward pressure in the short term.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80